Gene Vision
  • Information and support
    • Chatbot
    • The eye
    • How to see a genetic eye specialist?
    • Coping with sight loss
    • Eye Clinic Liaison Officers (ECLOs)
    • Education and learning
    • Employment support
    • Family support service (FSS)
    • Registration for sight impairment
    • Charles Bonnet Syndrome (CBS)
    • Driving and alternative transport
  • Conditions
  • Genetics
    • Genetics basics and inheritance pattern
    • Genetic counselling and genetic testing: for patients
    • Family planning
    • Genetic counselling: for professionals
    • Clinical genetic testing: for professionals
  • Gene cards
    • Retinal dystrophies
    • Microphthalmia, anophthalmia, coloboma (MAC) and aniridia
    • Cataract and lens associated
    • Anterior segment dysgenesis including glaucoma
    • Albinism
  • Research
    • Therapies under research
    • Searching for current research or trials
    • Research Opportunities At Moorfields
  1. Home
  2. Knowledge Base
  3. RPE65
Searching...
  • Gene therapy

    Gene therapy works by replacing the defective mutated gene in the affected cells with a normal healthy copy, primarily in inherited retinal disorders.
  • Leber congenital amaurosis (LCA)/Early onset severe retinal dystrophy (EOSRD): for professionals

    LCA/EOSRD form part of a spectrum of inherited retinal dystrophies that cause severe visual loss at an early age. There is now an approved retinal gene therapy called Luxturna for patients with RPE65 mutations.
  • RPE65 gene

  • Leber Congenital Amaurosis (LCA): for patients

    LCA describes a group of inherited retinal conditions that cause severe sight impairment or blindness from birth. There is now an approved treatment called Luxturna for patients with RPE65 mutations.
  • RPE65 – retinal degeneration: for patients

    Mutations in the RPE65 can cause either leber congenital amaurosis or retinitis pigmentosa. Night blindness is one of the earliest symptoms but patients tend to suffer central visual loss later. Gene therapy (Luxturna) is now approved in the UK for patients with mutations in the RPE65 gene.
  • Luxturna treatment in the UK

    Treatment centres in the UK currently offering Luxturna treatment under the NHS.

©2020 Copyright Gene Vision. Read our privacy policy and accessibility statement.